RE:RE:3 scenarios by the end of Sept It looks like Actavis (Teva) is not going to launch there generic version of Absorica. They have rights to launch there generic version 9 months early under a previous agreement. The market must be too small for them now which is great News for Cipher and Sun. With no competition to reduce prices to match the generic version revenue should see an uptick with the LD version now in full launch. The revenue was forecast to be cut by 30 percent due to the losses from the generic version. That puts us into 4th quarter 2021 before any competition if this holds. Hopefully other generic pharmas are reluctant to drive into this space for the same reasons next year.